UP-TO-DATE MANAGEMENT OF LUNG DISEASE IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS
Abstract
Cystic fibrosis (CF) is a multi-organ disease, affecting mostly lungs and gastrointestinal tract. Data from patient registries show that the survival of patients with CF has progressively improved over the past several decades, as a result of advances in antibiotic treatment, supplementation of pancreatic enzymes, better nutrition and a holistic approach to treatment in CF centres.
The purpose of this review is to survey recent developments in the treatment of lung disease in children and adolescents with CF.
We describe newborn screening for CF.
When chronic respiratory insufficiency occurs, lung transplantation becomes a very important issue.
Lung disease is the most common cause of morbidity and mortality in CF patients. Emerging new therapies are targeted at all points in the pathogenesis of lung disease, from drugs that treat infection and inflammation in the airways to gene transfer studies and to drugs that augment airway surface liquid height. A number of antibacterial agents formulated for inhalation are at various stages of study and there are several anti-inflammatory candidate drugs in clinical trials. The most important development in the recent years is modulation of the abnormal protein that causes CF, the cystic fibrosis transmembrane regulator (CFTR), where drugs are targeted at specific defects in the transcription, processing or functioning.
When chronic respiratory insufficiency occurs, lung transplantation becomes a very important issue. The role of the CF nurse, who has responsibilities in educating and teaching clinical skills to patients and families, is described.
Downloads
References
Balfour-Lynn IM. Newborn screening for cystic fibrosis: evidence for benefit. Arch Dis Child 2008; 93: 7-10.
Southern KW, Mérelle MM, Dankert-Roelse JE, et al. Newborn screening for cystic fibrosis. Cochrane Database Syst Rev 2009(1);CD001402.
Wang SS, O' Leary LA, Fitzsimmons SC, Khoury MJ. The impact of early cystic fibrosis diagnosis on pulmonary function in children. J Pediatr 2002; 141:804-810.
Sanders DB, Lai HJ, Rock MJ and Farrell PM. Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies. J Cyst Fibros 2012; 11:150-3.
Castellani C, Southern KW, Brownlee K, et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2009; 8:153-73.
European cystic fibrosis society Patient registry. Dosegljivo na: http://www.ecfs.eu/projects/ecfs-patient-registry/intro
Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326:1187-91.
Ramsey B, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340:23-30.
Cystic Fibrosis Foundation Patient Registry. Annual data report 2006; 2006. Dosegljivo na: www.cff.org/LivingWithCF/CareCenterNetwork/PatientRegistry/
Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology 2007; 153:917-23.
Döring G, Høiby N, et al. For the Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004; 3:67-91.
Hansen CR, Pressler T, Nielsen KG, Jensen PØ, Bjarnsholt T, Høiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros. 2010;9:51-8.
Dalbøge CS, Hansen CR, Pressler T, Høiby N and Johansen HK. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. J Cyst Fibros 2011; 10:318-25.
Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005; 4:49-54.
Taccetti G, Campana S, Festini F, et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26:458-61.
Döring G, et al. For the Consensus Committee. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16:749-67.
Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121:55-63.
Ratjen F, Brockhaus F, Angyvalosi G. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J Cyst Fibros 2009; 8:361-9.
Stelmach I, Korzeniewska A, Stelmach W. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland. Respiration 2008; 75: 178-81.
Wertz DA, Chang CL, Stephenson JJ, Zhang J, Kuhn RJ. Economic impact of tobramycin in patients with cystic fibrosis in a managed care population. J Med Econ. 2011;14:759-68.
Sawicki GS, Signorovitch JE, Zhang J, et al. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 2012;47:44-52.
Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Medicine 2011; 9:32.
Jones AM, Helm JM. Emerging treatments in cystic fibrosis. Drugs 2009; 69:1903-10.
Lewis EC. Expanding the clinical indications for α (1)-antitrypsin therapy. Mol Med 2012;18:957-70
Oerman CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-months study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45:1121-34.
Trapnell BC, Mc Colley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med 2012; 185: 171-8.
Littlewood KJ, Higashi K, Jansen JP, Capkun-Niggli G, Balp MM, Doering G, Tiddens HA, Angyalosi G. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cysticfibrosis. J Cyst Fibros 2012;11:419-26.
Balough K, McCubbin M, Weinberger M, et al. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995; 20:63-70.
Prescott WA Jr, Johnson CE. Antiinflammatory therapies for cystic fibrosis: past, present, and future. Pharmacotherapy 2005; 25:555-73.
Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360:978-84.
Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2011;12: CD002203.
Dmello D, Nayak RP, Matuschak GM. Stratified assessment of the role of inhaled hypertonic saline in reducing cystic fibrosis pulmonary exacerbations: a retrospective analysis. BMJ Open 2011; 1:e000019.
Ratjen F. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 2009; 54:595-602.
Daviskas E, Rubin BK. Effect of inhaled dry powder mannitol on mucus and its clearance. Expert Rev Respir Med 2013;7:65-75.
Bilton D, Robinson P, Cooper P, Gallagher CG, Kolbe J, Fox H, Jaques A, Charlton B; CF301 Study Investigators. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38:1071-80.
Aitken ML, Bellon G, De Boeck K, Flume PA, Fox HG, Geller DE, Haarman EG, Hebestreit HU, Lapey A, Schou IM, Zuckerman JB, Charlton B; CF302 Investigators. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012;185 :645-52.
Burrows EF, Southern KW, Noone PG. Sodium channel blockers for cystic fibrosis. Cochrane Database Syst Rev 2012 Mar 14;3:CD005087.
Cuthbert AW. New horizons in the treatment of cystic fibrosis. Br J Pharmacol 2010; 163: 173-83.
Kim Chiaw P, Eckford PD, Bear CE. Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy. Essays Biochem 2011;50 :233-48.
Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72.
Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with G551D mutation. Am J Respir Crit Care Med 2013; 187: 1219 -25.
Pettit RS. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Ann Pharmacother 2012; 46:1065-75.
Kerem E, Konstan MW, De Boeck K, et al. For the Cystic Fibrosis Ataluren Study Group. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2014: S2213-2600(14)70100-6. doi: 10.1016/S2213-2600(14)70100-6.
Armstrong DK, Cunningham S, Davies JC, Alton EW. Gene therapy in cystic fibrosis. Arch Dis Child 2014;99:465-8.
Kmietowicz Z. Trial is started to see whether gene therapy can improve lung function in cystic fibrosis. BMJ 2012; 344:e2141.
Rosenblatt RL. Lung transplantation in cystic fibrosis. Respir Care 2009;54 (6):777-86.
Braun AT, Merlo CA. Cystic fibrosis lung transplantation. Curr Opin Pulm Med 2011; 17(6):467-72.
Aigner C, Jaksch P, Seebacher G, Mazhar S, Wisser W, Klepetko W. Cystic fibrosis and lung transplantation--determination of the survival benefit. Wien Klin Wochenschr 2004. 116 (9-10):318-21.
Lang G, Taghavi S, Aigner C, Rényi-Vámos F, Jaksch P, Augustin V, Nagayama K, Ghanim B, Klepetko W. Primary lung transplantation after bridge with extracorporeal membrane oxygenation: a plea for a shift in our paradigms for indications. Transplantation 2012; 93:729-36.
Aurora P, Boucek MM, Christie J, et al. Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric lung and heart/lung transplantation report—2007. Journal of Heart and Lung Transplantation 2007;26 :1223–8.
Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report—2007. Journal of Heart and Lung Transplantation. 2007;26:782–95.
Aurora P, Carby M, Sweet S. Selection of cystic fibrosis patients for lung transplantation. Current Opinion in Pulmonary Medicine 2008;14:589–94.
Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation 2006;25:745–55.
Olland A, Falcoz PE, Kessler R, Massard G. Should cystic fibrosis patients infected with Burkholderia cepacia complex be listed for lung transplantation? Interact Cardiovasc Thorac Surg. 2011 Dec;13(6):631-4. Epub 2011.
Elizur A, Sweet SC, Huddleston CB, Gandhi SK, Boslaugh SE, Kuklinski CA, Faro A. Pre-transplant mechanical ventilation increases short-term morbidity and mortality in pediatric patients with cystic fibrosis. J Heart Lung Transplant. 2007;26(2):127-31.
Standards of care and good clinical practice for the physiotherapy management of cystic fibrosis. Association of Chartered Physiotherapists in Cystic Fibrosis (ACPCF), June 2011. Dosegljivo na: http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/Physio_standards_of_care.pdf, dos.
Clinical Guidelines: Care of children with cystic fibrosis. Royal Brompton Hospital. Dosegljivo na: www.rbht.nhs.uk/childrencf. 2011; 5th edition.
Murphy S. Respiratory medication. Respir Nursing 2001; 5: 81-103.
Heijerman H, Westerman E, Conway S, Touw D, Döring G: consensus working group. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J Cyst Fibros 2009;8:295-315.
Tiddens H. Inhalation therapy in CF. ERS School course on cystic fibrosis 2006; 221 – 228.
Smaldone GC, Sangwan S, Shah A. Facemask design, facial deposition, and delivered dose of nebulized aerosols. J Aerosol Med 2007; 20: S66 – S77.
Erzinger S, Schueepp KG, Brooks-Wildhaber J, Devadason SG, Wildhaber JH. Facemask and aerosol delivery in vivo. J Aerosol Med 2007; 20:S78– S83.
O‘Malley CA, VanddenBranden SL, Zheng XT, Polito AM, McColley SA. A day in life of a nebulizer: Surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting. Respiratory Care 2007; 52:258-62.
Borinc BA, Brecelj J, Bratanič N, Homan M, Homšak M, Jenko K, et al. Smernice za obravnavo otrok s cistično fibrozo. Zdrav Vestn 2008; 77:679-92.
Burkholderia Cepacia complex, suggestions for prevention and infection control. Report of the UK Cystic Fibrosis Trust Infection Control Group. September 2004;dosegljivo na: http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C_Burkholderia_cepacia_Sep_2004.pdf; 12.10.2012.
Pseudomonas aeruginosa infection in people with cystic fibrosis, suggestions for prevention and infection control. Report of theUK Cystic Fibrosis Trust Infection Control Group. November 2004;dosegljivo na: http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C_Pseudomonas_aeruginosa_Nov_04.pdf; 12.10.2012.
Saiman L. Infection prevention and control in cystic fibrosis. Curr Opin Infect Dis 2011; 24:390-5.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
